REG - Ondine Biomedical - Appointment of non-Board Interim CFO

Ondine BiomedicalAnnouncement

09/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250509:nRSI9704Ha&default-theme=true

RNS Number : 9704H  Ondine Biomedical Inc.  09 May 2025

9 May 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine", or the "Company")

Appointment of non-Board Interim CFO

Ondine Biomedical Inc. (AIM: OBI) announces the appointment of Alan Thomas as
non-Board interim Chief Financial Officer (CFO) of the Company, effective
immediately. Mr. Thomas succeeds Michael Behlke, who is stepping down from his
role as CFO and COO for personal reasons. Ondine extends its sincere
appreciation to Mr. Behlke for his contributions and wishes him the very best
for the future.

Mr. Thomas is a highly accomplished financial executive with more than 25
years of leadership experience across public and private organizations in the
healthcare, biotechnology, and infrastructure sectors, from high-growth
start-ups to large multinational and public sector organizations. His prior
roles include CFO at Maximus Canada Inc., a division of NYSE-listed Maximus
Inc., and BC Transit, as well as Head of Finance at BC Emergency Health
Services. He has also served as CFO and financial consultant to emerging and
growth-stage firms including Aspreva Pharmaceuticals, Aurinia Pharmaceuticals,
and Geno 10X, where he played key roles in fundraising, valuation, investor
relations, and IPO preparation, notably during Aspreva's public listing.

 

Throughout his career, Mr. Thomas has provided strategic financial leadership
and driven performance improvements through capital planning and
enterprise-wide transformation initiatives. His experience includes managing
large-scale budgets, implementing integrated business systems (including ERP
platforms), and delivering operational efficiencies through procurement
modernization and other enterprise initiatives.

 

Mr. Thomas will apply his deep experience in financial strategy, governance,
and planning to support Ondine's next phase of growth and the continued
expansion of its light-activated antimicrobial technology in key markets.

 

Alan Thomas, interim CFO of Ondine Biomedical, commented:

"Ondine is entering an exciting phase of development, with growing momentum
behind its breakthrough technology. I'm looking forward to working with the
team to help drive the Company's strategic and financial objectives forward."

COO duties will be assumed by current executive management.

 

Enquiries:

 Ondine Biomedical Inc.                                     www.ondinebio.com
 Carolyn Cross, CEO                                         Via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                              +44 (0)20 7409 3494

 RBC Capital Markets (Broker)
 Kathryn Deegan                                             +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard                           +44 (0)77 1000 5910

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies (also known as 'photodisinfection').
Ondine has a pipeline of investigational products, based on its proprietary
photodisinfection technology, in various stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada and several other countries under the name Steriwave(®).
In the US, it has been granted Qualified Infectious Disease Product
designation and Fast Track status by the FDA and is currently undergoing
clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCSSDFWAEISEFI